Drilldown: Medicines

25B-NBOH (1) · 25B-NBOMe (1) · 25C-NBOH (1) · 25C-NBOMe (1) · 25I-NBOH (1) · 25I-NBOMe (1) · 25N-NBOMe (1) · 2C-B (1) · 2C-B-FLY (1) · 2C-C (1) · 2C-D (1) · 2C-E (1) · 2C-I (1) · 2C-P (1) · 2C-T-2 (1) · 2C-T-7 (1) · Allopurinol (1) · Allylescaline (1) · Bromo-DragonFLY (1) · Colchicine (1) · DOB (1) · DOC (1) · DOI (1) · DOM (1) · Escaline (1) · Methallylescaline (1) · Proscaline (1) · TMA-2 (1)

None (25) · Colcrys, Mitigare, Gloperba, Lodoco (low-dose cardiovascular) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Zyloprim, Aloprim (IV) (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (2) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Very potent 5-HT2A agonist; long duration (1)

None (26) · '"`UNIQ--vote-0000030B-QINU`"', '"`UNIQ--vote-0000030C-QINU`"', '"`UNIQ--vote-0000030D-QINU`"', '"`UNIQ--vote-0000030E-QINU`"' (1) · '"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"' (1)

None (26) · 100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease) (1) · Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction (1)

None (26) · 0.6 mg tablets; 0.6 mg/5 mL solution; 0.5 mg tablets (Lodoco) (1) · 100 mg, 300 mg tablets; IV 500 mg vial (1)

None (26) · 1.8 mg in any 1-hour period (acute gout); 1.2 mg/d (prophylaxis with renal/hepatic impairment); much lower with strong CYP3A4 or P-gp inhibitors (1) · 800 mg/d (rarely needed) (1)

None (25) · insufflated (1) · IV (1) · Oral (2) · Oral (IV form withdrawn US 2009 due to fatal toxicity reports) (1) · PR (1)

None (25) · 45-75 min (oral) (1) · Anti-inflammatory effect within 24 hours of gout flare onset; loses effectiveness if delayed (1) · Serum urate falls gradually over days to weeks; acute flare prevention requires colchicine cover during initiation (1)

None (25) · 24 hours (1) · 4-8 h (1) · Hours per dose (1)

None (25) · 1-2 hours (parent); 18-30 hours for active metabolite oxypurinol'"`UNIQ--ref-0000030F-QINU`"' (1) · Not well characterized (1) · ~27-31 hours; markedly prolonged in renal/hepatic impairment and with CYP3A4 or P-gp inhibitors'"`UNIQ--ref-00000C72-QINU`"' (1)

None (25) · Not well characterized (1) · ~45% (oral)'"`UNIQ--ref-00000C73-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-00000310-QINU`"' (1)

None (25) · Limited safety data; weigh benefit individually.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1) · Used in FMF in pregnancy; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (25) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (2)